InBody Co.,Ltd (041830.KQ)
KRW 23700.0
(-0.42%)
KRW 23700.0
(-0.42%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 44.25 Billion KRW | -3.95% |
| 2022 | 46.07 Billion KRW | 14.37% |
| 2021 | 43.76 Billion KRW | 71.95% |
| 2020 | 23.51 Billion KRW | -25.75% |
| 2019 | 32.3 Billion KRW | 22.82% |
| 2018 | 25.69 Billion KRW | -3.09% |
| 2017 | 26.65 Billion KRW | 11.44% |
| 2016 | 23.78 Billion KRW | 11.29% |
| 2015 | 21.37 Billion KRW | 90.8% |
| 2014 | 11.2 Billion KRW | 51.36% |
| 2013 | 7.4 Billion KRW | 32.75% |
| 2012 | 5.57 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 11.25 Billion KRW | 27.11% |
| 2024 Q2 | 10.77 Billion KRW | -3.09% |
| 2023 Q2 | 9.79 Billion KRW | -15.44% |
| 2023 Q1 | 11.58 Billion KRW | -11.94% |
| 2023 FY | - KRW | -3.95% |
| 2023 Q3 | 13.84 Billion KRW | 41.27% |
| 2023 Q4 | 9.02 Billion KRW | -34.77% |
| 2022 Q3 | 8.88 Billion KRW | -21.35% |
| 2022 Q1 | 12.75 Billion KRW | 26.28% |
| 2022 FY | - KRW | 14.37% |
| 2022 Q4 | 13.15 Billion KRW | 48.02% |
| 2022 Q2 | 11.3 Billion KRW | -11.39% |
| 2021 Q4 | 10.1 Billion KRW | 12.38% |
| 2021 Q1 | 11.34 Billion KRW | 54.22% |
| 2021 FY | - KRW | 71.95% |
| 2021 Q2 | 9.85 Billion KRW | -13.06% |
| 2021 Q3 | 8.98 Billion KRW | -8.85% |
| 2020 Q1 | 6.82 Billion KRW | 10.57% |
| 2020 Q3 | 7.9 Billion KRW | 448.77% |
| 2020 Q4 | 7.35 Billion KRW | -6.97% |
| 2020 FY | - KRW | -25.75% |
| 2020 Q2 | 1.44 Billion KRW | -78.88% |
| 2019 Q4 | 6.16 Billion KRW | -29.35% |
| 2019 Q3 | 8.73 Billion KRW | -10.7% |
| 2019 FY | - KRW | 22.82% |
| 2019 Q1 | 6.94 Billion KRW | 20.01% |
| 2019 Q2 | 9.77 Billion KRW | 40.77% |
| 2018 Q1 | 5.02 Billion KRW | -38.06% |
| 2018 Q3 | 7.78 Billion KRW | 9.73% |
| 2018 Q2 | 7.09 Billion KRW | 41.34% |
| 2018 FY | - KRW | -3.09% |
| 2018 Q4 | 5.78 Billion KRW | -25.67% |
| 2017 FY | - KRW | 11.44% |
| 2017 Q4 | 8.1 Billion KRW | 8.86% |
| 2017 Q2 | 6.2 Billion KRW | 26.76% |
| 2017 Q1 | 4.89 Billion KRW | 2.36% |
| 2017 Q3 | 7.44 Billion KRW | 20.06% |
| 2016 Q4 | 4.78 Billion KRW | -5.66% |
| 2016 FY | - KRW | 11.29% |
| 2016 Q3 | 5.06 Billion KRW | -10.54% |
| 2016 Q2 | 5.66 Billion KRW | -31.56% |
| 2016 Q1 | 8.27 Billion KRW | 31.82% |
| 2015 Q4 | 6.27 Billion KRW | 4.12% |
| 2015 FY | - KRW | 90.8% |
| 2015 Q1 | 4.55 Billion KRW | 248.9% |
| 2015 Q2 | 4.46 Billion KRW | -1.92% |
| 2015 Q3 | 6.03 Billion KRW | 35.05% |
| 2014 Q1 | 3.75 Billion KRW | 202.64% |
| 2014 Q2 | 3.41 Billion KRW | -9.07% |
| 2014 Q3 | 2.67 Billion KRW | -21.53% |
| 2014 Q4 | 1.3 Billion KRW | -51.24% |
| 2014 FY | - KRW | 51.36% |
| 2013 Q1 | 3.09 Billion KRW | 400.2% |
| 2013 Q4 | 1.23 Billion KRW | -41.83% |
| 2013 FY | - KRW | 32.75% |
| 2013 Q2 | 1.21 Billion KRW | -60.67% |
| 2013 Q3 | 2.13 Billion KRW | 74.94% |
| 2012 Q3 | 1.6 Billion KRW | 0.0% |
| 2012 Q4 | 619.11 Million KRW | -61.36% |
| 2012 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Osang Healthcare Co.,Ltd | 157.89 Billion KRW | 71.969% |
| Curexo Inc. | -2.75 Billion KRW | 1707.263% |
| Seegene, Inc. | 35.65 Billion KRW | -24.127% |
| i-SENS, Inc. | 24.14 Billion KRW | -83.304% |
| Ray Co., Ltd. | 7.62 Billion KRW | -480.499% |
| Gencurix Inc. | -18.09 Billion KRW | 344.618% |
| Sugentech Inc. | -12.13 Billion KRW | 464.823% |
| L&C Bio Co., Ltd | 13.4 Billion KRW | -230.231% |